NAS10028,621+1.56%S&P7,714+1.92%GOLD$4,077+3.45%BTC$80,598+4.21%VIX16.86−19.06%latest tape · as of 18:06 UTC
The Screen · Technology · Information Technology Services
Accenture
ACN · a US exchange · USD · Market cap $151.3B · 786,000 employees
Accenture plc provides strategy and consulting, industry X, song, and technology and operation services in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.46, read 2026-11-03
Ethical passes the values gate
Price254.56 USD
Fair value275.26
Ethical score84.3/100
Value readFairas of 3 Nov 2026
Our investment reviews on this name
2026-10-11Read Markup176.11+44.5% to today ✓Distribution gives way to Markup first Markup read since September
2026-10-02Read Distribution176.11+44.5% to today Markup gives way to Distribution first Distribution read since July
2026-08-20Read Markup170.73+49.1% to today ✓Distribution gives way to Markup after a 19% rise in 4 weeks
2026-07-20Read Distribution143.57+77.3% to today Markup gives way to Distribution after a 19% slide in 3 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Accenture holds its Markup at $254.56. Consolidating, no directional conviction, held for 22 days.
As held on the ledger · 2026-11-03
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 22 days
Price at the screen
$254.56
Valuation
18.23 trailing · 15.56 forward price to earnings
Values screen
PASS· score 84.3
Beta
1.10
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
12.51%
Below 33%
Interest-bearing debt is just 12.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
1.10%
Below 33%
Cash held in interest-bearing accounts and securities is 1.1% of assets, under the one-third limit.
Pass
Receivables
37.53%
Below 49%
Money owed to the company is 37.5% of assets, under the 49% limit.
Pass
Revenue purity
0.48%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Accenture clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-11-04. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when ACN's ethical verdict changes
Today ACN passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 3 Nov 2026: it trades at roughly a 7% discount to our $275.26 fair value, moderate competitive moat, 6.20% revenue growth.
Fair value range in USD, drawn from the 2026-11-03 screen. The gold marker is the market price at the same screen. A 7.5% discount to the base estimate.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Ireland and to currency swings.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ACN trades on a US exchange (the company is based in Ireland). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-01Markup$258.24+14.8%Entry 12
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 14.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading overbought. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (24 analysts) rates it buy, with a mean price target of $230.
2026-10-25Markup$224.92+0.0%Entry 11
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (24 analysts) rates it buy, with a mean price target of $228.
2026-10-18Markup$224.92+27.7%Entry 10
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 27.7% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (24 analysts) rates it buy, with a mean price target of $225.
2026-10-11Markup · changed$176.11+0.0%Entry 9
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (24 analysts) rates it buy, with a mean price target of $224.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (24 analysts) rates it buy, with a mean price target of $193.
2026-09-19Markup$179.03+4.9%Entry 7
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $185.
2026-08-20Markup · changed$170.73+18.9%Entry 6
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.9% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 19.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
2026-07-18Markup$178.25+0.0%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
2026-07-16Markup$178.25+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 46%. Our forward projection puts the odds of a 10% gain over the next month near 12%. The street (25 analysts) rates it buy, with a mean price target of $181.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
